Guo‐Ming Shi

6.6k total citations · 1 hit paper
71 papers, 3.0k citations indexed

About

Guo‐Ming Shi is a scholar working on Surgery, Oncology and Molecular Biology. According to data from OpenAlex, Guo‐Ming Shi has authored 71 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Surgery, 25 papers in Oncology and 24 papers in Molecular Biology. Recurrent topics in Guo‐Ming Shi's work include Cholangiocarcinoma and Gallbladder Cancer Studies (24 papers), Hepatocellular Carcinoma Treatment and Prognosis (16 papers) and Peptidase Inhibition and Analysis (9 papers). Guo‐Ming Shi is often cited by papers focused on Cholangiocarcinoma and Gallbladder Cancer Studies (24 papers), Hepatocellular Carcinoma Treatment and Prognosis (16 papers) and Peptidase Inhibition and Analysis (9 papers). Guo‐Ming Shi collaborates with scholars based in China, Ethiopia and United States. Guo‐Ming Shi's co-authors include Ai‐Wu Ke, Jia Fan, Jiabin Cai, Jia‐Cheng Lu, Xiaoyong Huang, Pengfei Zhang, Chao Gao, Jian Zhou, Zhen‐Bin Ding and Xiaojun Guo and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Guo‐Ming Shi

69 papers receiving 3.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cancer cell-derived exosomal circUHRF1 induces natural killer cell exhaustion and may cause resistance to anti-PD1 therapy in hepatocellular carcinoma

2020 465 citations Pengfei Zhang, Chao Gao et al. Molecular Cancer profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Guo‐Ming Shi China	30	1.8k	1.2k	740	483	446	71	3.0k
Li Zhou China	32	1.5k 0.9×	1.0k 0.8×	905 1.2×	293 0.6×	324 0.7×	118	2.7k
Guo‐Huan Yang China	17	952 0.5×	773 0.6×	732 1.0×	504 1.0×	310 0.7×	38	2.1k
Binkui Li China	30	1.3k 0.7×	950 0.8×	743 1.0×	932 1.9×	503 1.1×	103	2.8k
Mu-Yan Cai China	33	1.7k 1.0×	965 0.8×	735 1.0×	141 0.3×	471 1.1×	58	2.9k
Camilla Pilati France	19	1.1k 0.6×	617 0.5×	1.1k 1.5×	542 1.1×	408 0.9×	32	2.7k
Seung Myung Dong South Korea	31	2.0k 1.1×	784 0.6×	937 1.3×	214 0.4×	260 0.6×	49	3.0k
Shao‐Lai Zhou China	30	1.6k 0.9×	1.3k 1.1×	1.4k 1.9×	578 1.2×	515 1.2×	58	3.7k
Naoki Ikenaga Japan	25	830 0.5×	502 0.4×	962 1.3×	507 1.0×	605 1.4×	75	2.3k
Hee Jung An South Korea	27	1.3k 0.7×	766 0.6×	818 1.1×	142 0.3×	313 0.7×	76	2.5k
Carla Cicchini Italy	26	1.6k 0.9×	926 0.7×	418 0.6×	359 0.7×	430 1.0×	61	2.4k

Countries citing papers authored by Guo‐Ming Shi

Since Specialization

Citations

This map shows the geographic impact of Guo‐Ming Shi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guo‐Ming Shi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guo‐Ming Shi more than expected).

Fields of papers citing papers by Guo‐Ming Shi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Guo‐Ming Shi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guo‐Ming Shi. The network helps show where Guo‐Ming Shi may publish in the future.

Co-authorship network of co-authors of Guo‐Ming Shi

This figure shows the co-authorship network connecting the top 25 collaborators of Guo‐Ming Shi. A scholar is included among the top collaborators of Guo‐Ming Shi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Guo‐Ming Shi. Guo‐Ming Shi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fu, Shiyan, Wenrun Li, Guo‐Ming Shi, et al.. (2025). Biomimetic polydopamine nanoassembly regulates M2 macrophage polarization to alleviate radiation-induced pulmonary fibrosis via the PI3K/AKT/S100A4 pathway. Chemical Engineering Journal. 506. 159980–159980. 2 indexed citations

Shi, Hui, Rong Gao, Wei Zhang, et al.. (2025). Liver-specific paraoxonase-1 alleviates regulatory T cell-driven immunosuppression via metabolic reprogramming in hepatocellular carcinoma. Nature Communications. 16(1). 11034–11034.

Gao, Zheng, Ying‐Hong Shi, Zheng Tang, et al.. (2023). Autophagy suppression facilitates macrophage M2 polarization via increased instability of NF-κB pathway in hepatocellular carcinoma. International Immunopharmacology. 123. 110685–110685. 9 indexed citations

Guo, Xiaojun, Xiaoyong Huang, Xuan Yang, et al.. (2023). Loss of 5-hydroxymethylcytosine induces chemotherapy resistance in hepatocellular carcinoma via the 5-hmC/PCAF/AKT axis. Cell Death and Disease. 14(2). 79–79. 14 indexed citations

Jing, Xiaorong, Yihua Chen, Guo‐Ming Shi, et al.. (2020). Down-regulation of USP8 Inhibits Cholangiocarcinoma Cell Proliferation and Invasion. SHILAP Revista de lepidopterología. 4 indexed citations

Li, Shuangqi, Feizhen Wu, Jiabin Cai, et al.. (2020). TET 2 promotes anti‐tumor immunity by governing G‐ MDSC s and CD 8 ⁺ T‐cell numbers. EMBO Reports. 21(10). e49425–e49425. 34 indexed citations

Shi, Jun, et al.. (2020). Circulating Tumor Cells as a Biomarker to Assist Molecular Diagnosis for Early Stage Non-Small Cell Lung Cancer. SHILAP Revista de lepidopterología. 3 indexed citations

Li, Xiao‐Long, Xiao‐Dong Zhu, Xuefeng Liu, et al.. (2020). A prospective study of the effect of terlipressin on portal vein pressure and clinical outcomes after hepatectomy: A pilot study. Surgery. 167(6). 926–932. 8 indexed citations

Zhou, Qiang, Hao Cai, Minghao Xu, et al.. (2020). Do the existing staging systems for primary liver cancer apply to combined hepatocellular carcinoma-intrahepatic cholangiocarcinoma?. Hepatobiliary & pancreatic diseases international. 20(1). 13–20. 11 indexed citations

10.

Huang, Xiaoyong, Pengfei Zhang, Chuanyuan Wei, et al.. (2020). Circular RNA circMET drives immunosuppression and anti-PD1 therapy resistance in hepatocellular carcinoma via the miR-30-5p/snail/DPP4 axis. Molecular Cancer. 19(1). 92–92. 178 indexed citations

11.

Zhang, Pengfei, Chao Gao, Xiaoyong Huang, et al.. (2020). Cancer cell-derived exosomal circUHRF1 induces natural killer cell exhaustion and may cause resistance to anti-PD1 therapy in hepatocellular carcinoma. Molecular Cancer. 19(1). 110–110. 465 indexed citations breakdown →

12.

Peng, Rui, Pengfei Zhang, Xuan Yang, et al.. (2019). Overexpression of RNF38 facilitates TGF-β signaling by Ubiquitinating and degrading AHNAK in hepatocellular carcinoma. Journal of Experimental & Clinical Cancer Research. 38(1). 113–113. 45 indexed citations

13.

Sun, Shaoyang, Jingjing Wang, Fei Fei, et al.. (2018). Canonical Wnt Signaling Remodels Lipid Metabolism in Zebrafish Hepatocytes following Ras Oncogenic Insult. Cancer Research. 78(19). 5548–5560. 46 indexed citations

14.

Huang, Cheng, Xiao‐Dong Zhu, Yuan Ji, et al.. (2017). Microvascular invasion has limited clinical values in hepatocellular carcinoma patients at Barcelona Clinic Liver Cancer (BCLC) stages 0 or B. BMC Cancer. 17(1). 58–58. 45 indexed citations

15.

Dong, Zhao‐Ru, Dong Sun, Guo‐Ming Shi, et al.. (2017). Preoperative Albumin-Bilirubin Score for Postoperative Solitary Hepatocellular Carcinoma within the Milan Criteria and Child-Pugh A Cirrhosis. Journal of Cancer. 8(18). 3862–3867. 24 indexed citations

16.

Huang, Xiaoyong, Guo‐Ming Shi, Ranjan Prasad Devbhandari, et al.. (2012). Low Level of Low-Density Lipoprotein Receptor-Related Protein 1 Predicts an Unfavorable Prognosis of Hepatocellular Carcinoma after Curative Resection. PLoS ONE. 7(3). e32775–e32775. 35 indexed citations

17.

Huang, Xiaoyong, Ai‐Wu Ke, Guo‐Ming Shi, et al.. (2010). Overexpression of CD151 as an adverse marker for intrahepatic cholangiocarcinoma patients. Cancer. 116(23). 5440–5451. 39 indexed citations

18.

Yang, Xin‐Rong, Yang Xu, Bin Yu, et al.. (2009). CD24 Is a Novel Predictor for Poor Prognosis of Hepatocellular Carcinoma after Surgery. Clinical Cancer Research. 15(17). 5518–5527. 129 indexed citations

19.

Ding, Zhen‐Bin, Ying‐Hong Shi, Jian Zhou, et al.. (2009). Liver‐intestine cadherin predicts microvascular invasion and poor prognosis of hepatitis B virus‐positive hepatocellular carcinoma. Cancer. 115(20). 4753–4765. 49 indexed citations

20.

Ke, Ai‐Wu, Guo‐Ming Shi, Jian Zhou, et al.. (2008). Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma #. Hepatology. 49(2). 491–503. 184 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact